© 2024 Alpha Spread Limited. All Rights Reserved.
www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.
You don't have any saved screeners yet
Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.
Good morning, everyone, and a very welcome to this webcast. I'm Johan Karlsson, I'm the Head of Investor Relations here at Essity. And together with me here today, I have our President and CEO, Magnus Groth; and also our CFO and Executive Vice President, Fredrik Rystedt. So today, we will first talk about yesterday's announcement. And after that, we will present the Q1 results. And after the presentation, we will open up for a Q&A session. [Operator Instructions] With that, I would like now to hand over to you, Magnus. So Magnus, please go ahead.
Thank you, Johan, and welcome, everybody, to this very busy presentation. We will start talking about strategic reviews that we initiated, but I also look very much forward to talking about the strong start of the year that we've had. We have good momentum throughout the company. But starting with the strategic review of ownership in Vinda and in our European private label tissue division. This is a strategic review that we're starting now with the aim of reducing our share of consumer tissue sales in the business. Consumer Tissue, as you know, is our most capital-intensive business with -- and also the business that is most dependent on fluctuating pulp prices and energy prices.
The review only covers these areas. We also have a substantial consumer tissue business with our branded products and also with our retail brand partners, which is very much our core business and where we continue to develop the business for the long term. We are looking at different options. We're early on in this process, so no decisions have been taken. We are not in a hurry. We are aiming to maximize value. So this is something we're doing step by step. And as you can see, this includes approximately 22% of Essity's sales, that's subject to this review.
Looking then to Vinda listed on the Stockholm Stock Exchange, market capitalization around SEK 34 billion. We own close to 52% in Essity and net sales last year was around SEK 25 billion. And the reason for including Vinda in this strategic review is the fact that 85% -- 83% of sales is Consumer Tissue. This is a fantastic company, well-managed, strong brands, strong market positions in attractive market, but this dependence on consumer tissue is the reason why we're including it in this review. We are working closely with the Board of Vinda. We have great relation since many years with the Board and the management team. And again, we are in no hurry, and we are aiming to maximize value when we pursue this strategic review.
Moving over then to the private label division, the Consumer Tissue Private Label division that has sales of close to SEK 10 billion last year. Seven production facilities, around 1,900 employees. We are finalizing the carve-out that we started 2 years ago. It's been a quite complex process, but we're at the end of that. So it's a good timing. It's also a good timing for the entire strategic review that we're performing now that the Private Label division is back on track after the pandemic and performing well. And I'm convinced that Vinda will have a strong second half of the year as raw material prices are expected to decrease in China and in Southeast Asia throughout the year.
So good timing. We're starting this review now, no hurry, we're aiming to maximize value here. So over to the interim report and a very strong start to the year, I think that sums it up pretty much. Price/mix, 18.6%, of which mix was 1.2%. We had positive mix in all parts of our business in spite of continuing to work very much with price increases shows the strength of our brands, our market positions. And as you can see there to the right a very strong improvement compared to the same quarter a year ago in all areas; sales growth, up 17.2%. This includes the acquisition of Knix for instance, that accounts for the acquisitions account for approximately 1.2% of the sales growth.
Knix is performing really, really well, growing over 20%, in line with our business plan. Adjusted EBITA more than doubled and the adjusted margin improved 200 basis points from 8.2% to 10.2%. I'm going through all these different numbers now because of the huge improvement. So it's a good slide to talk to. And of course, return on capital employed in the quarter up 370 basis points to 12.7%. So a very, very strong start of the year. Looking at that EBITA margin bridge, a good gross margin contribution gross margin is so important for us. That's what we need in order to be able to invest in advertising and promotion in our brands, in innovation, up 160 basis points, and this is in spite of continued headwinds from raw materials, energy and transport compared to a year ago of 880 basis points.
So for anyone questioning if we were able to compensate for the cost increases through pricing, through cost savings, through mix improvements, I think this shows that that's been possible and of course, something we will continue to work with in the quarters to come. A&P, doesn't impact the margin development growing in absolute terms, about 5.1% of sales. We expect to have higher A&P this year because we have a lot of good innovation coming. So looking forward to launching that in a proper way. And SG&A contributed positively as a percent of sales it's -- and EBITA, it's lower even though it's higher in absolute terms due to inflation, of course, ending at an adjusted EBITA margin of 10.2% in the first quarter.
This slide shows the quarterly development. And I think what the takeaway here from the sales growth is this is now the fifth consecutive quarter of the very, very good growth. And in most quarters, a combination of price, volume and mix and, of course, very much price throughout the last year, but also the other components. And we also see a pickup now in the adjusted EBITA margin with an exception in the third quarter -- second -- third quarter of last year when we, of course, had a huge energy spike in Europe that impacted the margin quite significantly, but also a nice trajectory here when it comes to the adjusted EBITA margin development.
Something that is becoming an opportunity for us is to continue to work with efficiency. You recognize these areas. These are areas we've been focusing on improving year over year over year with good outcome. But of course, it was more challenging during the pandemic and also during the supply chain disruptions last year. So we're really looking forward now to be able to focus more clearly again on energy savings, material rationalization, sourcing savings, waste reductions all the good things that's good for the environment and good for our business. We will also talk during the year about further footprint optimizations, Cure or Kill efforts. We are talking about one of those efforts in Professional Hygiene in this quarter, where we will take out some underperforming assets, which will have a EBITA margin improvement in the short to medium term associated with some restructuring costs.
Longer-term opportunities for improved performance and efficiency is definitely the integrated supply chain to improve our supply and demand planning, the S&OP process and so on through digitalization. And of course, with the inflation that we've seen -- been seeing now over the last year, an increased focus on SG&A costs going forward. So now that we are out of the turbulent times over the last couple of years, we are increasing focus on these specific areas and see new opportunities also as a consequence of our new organization that we put in place at the beginning of the year.
We always have a slide about innovation. The first quarter is typically not our strongest quarter. Still, we have some important innovation here. Maybe I had to focus on one, the Tork hand towel that you see there in the middle, it's quite gray or brown, and this is because 30% to 50% of the ingoing material is carton board. So it's a new source of fiber for us that's been difficult to convert to soft and absorbing hand house before, but we are now launching a new grade here that, of course, has a strong sustainability profile and also expands our fiber sourcing opportunities.
Finally, before handing over to Fredrik to go through the 3 different business areas, we continue with our initiatives and our progress in sustainability and also a number of awards and recognitions as we're used to, which remains, of course, a core pillar of our strategy. Welcome, Fredrik.
Thanks, Magnus. Thank you, and I will just take you through some of the details around our 3 business areas. And starting with Health & Medical, we've had a good start to the year with growth of 10.5% and growth was strong in all regions of the business area. And you will hear this some more, but we've had an impact from much lower volumes in our Russian business. And of course, also here for Health & Medical, we were impacted. So if you take out Russia, it's about 1%-or-so higher like-for-like sales, so roughly about 11.5%. Now as you will hear from me also in the other business areas, price and mix was generally strong. And starting with price, we had an increase this quarter in comparison to the same period last year of roughly about 10%. And also sequentially, just comparing to Q4, the increase was 1%.
So we continue with a good price momentum. And as Magnus you said it, the mix was positive, so close to 1% for Health & Medical. So we continue to benefit from our innovations that we put on the market. As you can see from the slide, volumes were stable. It's a bit different in different areas. So we had a minor decline in the Inco business where we left some low end or, I should say, low profitability contracts, but we had a corresponding or balancing growth in our Medical business and that growth volume-wise came from all 3 therapeutic areas.
And so we're quite happy with the development in that area. Now as you can see here, we had a very significant cost increase if we compare to last year. So in this case, the impact from an EBITA margin perspective was 560 basis points and we also did see an increase in SG&A coming from inflation. So from that perspective, the environment looks kind of similar, as you saw before. I'll come back a bit later to what we see for the immediate future. I'll do that at the end. So turning to Consumer Goods. We delivered a really, really strong growth, as you can see. So if you include the acquisition's 17.6% and the acquisitions that are included here as Magnus has alluded to, Knix and Modibodi, and we are very, very happy with the performance, not least in Knix with over 20%.
And it's the same thing here that we are impacted by the lower volumes in Russia. But here, we're also impacted by the fact that we left our diaper business in Colombia, as we have reported on before. So if you exclude these 2 unusual items, if I put it that way, the growth was a bit above 19%, so really, really strong growth. And the main driver, of course, positive mix here, but the main driver was pricing. So if you compare Q1 versus the same period last year, roughly about 18.5% or thereabout in just pure pricing. And also here sequentially we achieved another 1.3% of additional pricing. So it continues to be a good pricing market for us.
Now you can see here that volumes are down with 3.1%. And if you exclude the Russian business and the diaper business in Colombia, the reduction is roughly about 1.7%. And this is a reflection of a couple of different things. First of all, not least in Consumer Tissue, we continue to prioritize margin over growth. And we also have done the same for Baby, where we have exited 1 contract with much too low profitability as we've also reported on.
So this is where the volume declines mainly come from where we do just the opposite for inco and feminine, we grow volumes there and we are pleased with -- really pleased with the development in both and not least in feminine actually where we continue to take market share in Latin America, just a perhaps curiosity, we reached our highest market share ever in Mexico during the quarter, as an example. So here, I mean, obviously, the cost inflation is the highest. This is, of course, driven to a large extent by our Consumer Tissue business, so Pulp and Energy and the margin impact here was 1,050 basis points, so a considerable increase. And we also have, although, of course, much smaller an impact from inflation in SG&A.
So turning to our third business area, Professional Hygiene. This is actually where we've seen the strongest or highest organic sales growth. And if we exclude Russia here, the growth was roughly about 22%. This is driven by a fantastic price performance of 21%. Here, actually, prices were relatively flat sequentially, but year-on-year, upped by 21%. And the mix was actually 3% in this area. So really, really strong. You can see volumes are down. This is partly, again repeating what I've already said here a couple of times, due to Russia. But it's also, as we are going out of very low profitability business, it's impacted by that.
It's not everywhere. It's mainly in mature markets where volumes have come down a little bit. We can also see that emerging markets are continuing to do well, not least in LATAM, although we are, of course, much smaller there, but generally very good performance. Input costs the same here, 630 basis points, if you compare Q1 of 2023 versus last year, same period. So Pulp and Energy, as it is the -- as is the case also for consumer goods, they are the main driving factors and indirect cost, obviously impacted by inflation. So I'll touch upon the last point a bit. So of course, as you already know, as part of our strategy, we continue to premiumize our offering with more innovative and value-creating products.
And we will, as part of this general strategy, take some steps in our Professional Hygiene business. So what we are doing, we are planning to close some capacity used for our lower value creating and less innovative range. And as Magnus said, this will trigger some cost restructuring charges approximately in total SEK 410 million. And out of that, SEK 340 million, we will take as items affecting comparability in, in the second quarter. Now this will have some impact on growth also going forward. It's partly actually had a bit of an impact also in Q1, but we will see low single-digit impact throughout this year and the early part of next, but it will be very much margin accretive. So this is a project that we are planning that will yield some very good results. And over time, obviously, saying that we will replace these volumes that we are now taking out or plan to take out with more value-creating sales.
So I'll end with a couple of statements. Normally, we just give a bit of an outlook, it's always uncertain. But when it comes to our cost structure. So 3 items there, starting with raw material, energy and distribution. Generally, we see now that sequentially -- and I'll only comment on this sequentially. So what we will see now in Q2 for all 3 business areas, we will see lower cost sequentially in terms of raw material. It will be more so for consumer goods, but all 3 will be impacted positively. When it comes to energy, we see also there lower cost, and this is due to a couple of things. If you look at our hedging positions, when it comes to gas and electricity, it is roughly about 60% for Q2. And prices, if you compare to Q1, they're actually roughly on the same level within the hedging contract, but we also estimate lower market prices. So this is the reason why we also see lower energy cost. And then we also see lower distribution costs. So generally, the cost picture on the input side is positive. And of course, that's also generally seems to be the trend for the year as a whole. When we look at other costs, you will see in our report that we've had some negative impact from that. It's mainly inflationary driven, and it's also driven by distribution and other things. And we don't expect that if you look at it from a sequential basis to deteriorate further. So this is much more something that has happened, and we are expecting that to be more stable.
And then finally, SG&A. So a bit less positive picture there. We're not adding resources when it comes to SG&A, excluding A&P. It's more the inflationary environment that we live in and that will clearly lead to higher costs. So there is a negative thing there coming from SG&A. And as Magnus already said, we expect to have continuously throughout the year higher A&P. So I'll end there, Magnus, please.
Thanks. If you could move to the next slide, please. We've been very focused on our strong first quarter. It's a great quarter to talk about and also Fredrik has given an outlook for the next quarter. We have a longer-term perspective. We're focused on the next 3 to 5 years, not the least 2025, when we have set ourselves the target to achieve a return on capital employed above 17%. We are very committed to that. With this report, we've taken a good step in that direction, but we have more to do. Of course, for this year, there will be a big focus now on price management. We have proven that we can raise prices, and we have strong brands and market positions. I want to emphasize that again.
And of course, we will leverage that also now when we're entering a phase where we're talking about the cost margin gap and price management. And then for the longer term, to continue with innovations, building our brands, focusing on the growing channels, the prioritized growth areas in our business, both when it comes to categories and geographies, sustainability, efficiency and not least, winning with people and culture and where we are continuously strengthening our team in a very positive way. So all of this is leading to Essity being a leading global hygiene and health company. Thank you so much for listening. Let's head over to questions.
[Operator Instructions] We'll now take our first question from Victoria Nice, SG.
So my question relates to the strategic review. Just wondered if you could go into more detail on the rationale for both reviews and the likely timings? So you say you're in no hurry, but does that mean we shouldn't expect anything in 2023? And what are you assessing in the review, which might lead to a disposal versus retaining the business as it is? And also what could a potential Vinda sell-down strategy looks like? And then still related to that, I wondered if you could just talk about environment in China related to the competitive situation? And then finally, on the consumer tissue private label business, if you could indicate how the margin compares to the rest of the tissue business, that would be really helpful?
Okay. Thank you for that 1 question, Victoria. And we're just starting the strategic review now and what I wanted to underline really was not -- of course, this could take time because we always aim to execute quickly. But having said that, in this case, our clear focus is on maximizing value for us, for our shareholders and for all the shareholders of Vinda as well. So clearly, our focus on maximizing value. And we're starting this strategic review. So it's very early to get into the different alternatives and options. When it comes to the 2 businesses, the Private Label division in Europe has recovered well and it is operating at a good margin level. So very efficient, high-performing business. And Vinda is, of course, right now, as we could see from the Q report, struggling with remaining cost inflation. They're in a little bit of a different cycle than we are. So I expect that the second half of the year will be much stronger for Vinda than the first half. I'm ready for the next question.
Next up, we have Oskar Lindstrom.
Why only Vinda in the European private label consumer tissue business and not the other parts of the Consumer Tissue business, if the aim is to reduce your exposure to consumer tissue? Are there other reasons why that remaining part of the Consumer Tissue business in Europe is not part of this strategic review?
Yes. So just making the assumption, again, we're early in this process that where you take out the 2 businesses under the strategic review. Consumer Tissue would reduce from being today 41% of our sales as a total to 29%. So it's a considerable change there in the overall mix for the company. And actually, in such a future scenario, then consumer goods would be approximately half of our business, and where Consumer Tissue and Personal Care would be half and then the rest, Professional Hygiene and Health & Medical, so a very good balance in such a scenario. And the reason why we are not reviewing the rest of the Consumer Tissue business is because it's very strong brands. There's a lot of innovation here, a lot of sustainability, many opportunities actually with also the breakthrough technology that we had mentioned on the sustainability, uptake here also to really -- it is value creating today, and we believe it will be even more value creating. And it regards our own brands, but also the retail brands that we are working with a number of partners to develop in Europe. So that's a very good value-creating business and also the combined business in consumer goods of all the different categories with all the strong brands is a strength for us. So that's not subject to this review currently and not in the future. It's definitely part of our core business.
Just a follow-up on this. Is there an extent where some of your consumer tissue production facilities in Europe are joint with Professional Hygiene facilities, and that's a reason why it would be difficult to carve out the remaining consumer tissue?
Now this is part of the exercise we've been going through over the last 2 years. So we are finalizing that carve-out, which it's both organizationally, financially, legally and not least from an asset allocation perspective. So by early next year, also, the assets will be clearly separated and carved out. So the machine supplying private label volumes and the branded and retailer brand volumes. So that's what we've been working with over the last couple of years, and we are now finalizing that, and that's why we are announcing this today or yesterday.
[Operator Instructions] We will take the next question from Patrick Folan from Barclays.
Moving away just from a strategic view for now. Looking at pricing, how should we think about pricing evolving this year? I'm thinking that input cost inflation is coming down, what does that phasing look like? I guess, Health & Medical, big step up quarter-on-quarter. How should we think about pricing going ahead for the next -- into Q2 and kind of thinking about Professional Hygiene a bit flat quarter-on-quarter, is that peak pricing there?
Fredrik, do you want to talk to that? You started talking about the rest of the year.
Yes, thanks for the question. It's generally, of course, very difficult to talk about pricing. But what you can see there is that the price cost gap where margin expansion needs to continue to take place, and we're convinced that we're able to do that. But the comment on specific pricing is always difficult because it will depend on, of course, the cost development in the more long-term future. But generally, the price-cost gap needs to continue to widen, and we are committed to make that happen.
Next up, we have Linus Larsson from SEB.
Yes. And maybe then, after all, jumping back to the strategic review in your calculations, I wonder Essity ex Vinda and the European private label business, what's the ROCE change in the portfolio, if you maybe look over -- I don't know, if you look over a cycle or something like that? And also second to that, I mean, today, Vinda and Essity are highly integrated. Essity or SCA has sold Asian assets into Vinda in the past their licensing agreements. So I'm just a bit curious, and I understand it's an early stage, but if you could open up a little bit on your thinking as to the separation process potential down the road, are you going to maintain some sort of presence in Asia even without Vinda?
Regarding the first part of your question, what would Essity look like without these 2 businesses? It's too early to say. These are 2 capital-intensive parts of the business and with volatile earnings. But I think that's something that you can also kind of look at and estimate from all the numbers that we're continuously publishing. Second, yes, very good question. We would like to continue to cooperate with Vinda also then in kind of a hypothetical future where we are not longer the owner. We have a great working relationship, and we are -- they are licensing our brands, TENA, Tork and Tempo and Libresse, not the least, so global brands. And of course, we would like to see an outcome where we continue to be represented on the Chinese market and other markets with these strong brands. That's part of the strategic review that we are doing now, how we can achieve that going forward.
Next up, we have Simen Aas from DNB Markets.
So I have 1 question. You have previously talked about reaching around 50% emerging market share. And I know there is no formal decision on Vinda yet, but if you were to move out of Asia, what kind of region would you be looking at to increase the emerging market share?
So I think that our emerging market share today is around 37%, and it would be reduced to, in this hypothetical, again, scenario, 25%. It's still something that we're very much pursuing and gradually achieving an increased share of sales in emerging markets because, of course, the underlying growth rates have been at least historically higher. It's been looking a little bit different, actually recently. We are very, very successful, growing very nicely in Latin America. That continues to be a key focus area and an area where we are really doubling down, adding categories in countries and really kind of expanding our presence because based on the strong performance we already have. Former Eastern European countries is another area that's very important to us. And of course, with Australasia, our business there, we have some opportunities and also especially in Health & Medical to develop in Southeast Asia. So Southeast Asia, including China, remains very important for us as a growth area also going forward.
Next up, we have Charles Eden from UBS.
First one, just on cost savings in the quarter, if you could sort of set out how those progressed? And maybe if you can kind of give it on a gross savings basis because I know kind of the way you normally account for it, net of inflation kind of gives us a negative number when inflation is there? So comments on the cost savings would be appreciated. And then my second question, just a clarification. So am I right to assume this above 17% ROCE target is also holding true should the strategic review not result in a disposal of either of the assets you announced yesterday, i.e., that target of above 17% ROCE is something you're aiming to achieve as Essity exists and stands today?
Thanks. To the second question, the answer is absolutely yes. This is the path we're on with the business composition that we have to achieve above 17% return on capital employed during 2025 so -- by the latest. So that's definitely a yes to that question. And regarding gross and net cost savings. I happily hand over to you, Fredrik.
Thank you, Magnus. Yes, you're absolutely right. It's been quite difficult to kind of do the net because of the significant issues that had related to the past year or 2, but if you look at Q1 and you just take the gross efficiency gains in cost of goods sold, it was SEK 250 million or SEK 248 million to be exact. So we continue to do the underlying work and as before many, many projects leading to those efficiency gains. So that work continues with full force. It just isn't that visible. Hopefully, as I already alluded to, it will become more and more visible as we go forward in the following quarters.
Next up, we have Karel Zoete from Kepler Cheuvreux.
The first one is on the exit of Russia. You highlighted that. In the annual report, we can see it's still about 3% of revenues of the group. So what progress are you making? And what can we expect this year? The other question is then on market structure in Europe in Consumer Tissue. Can you speak about how potential sale of your private label business might alter the market structure here?
Okay. So yes, exit Russia, which is something we announced very quickly the last year after Russia's invasion of the Ukraine and some things that we've been working with ever since. This is very complex, of course, taking into account sanctions, taking account government approvals and so on. We're in the middle of that process, and we hope to be able to give some new information in the not-too-distant future. So we're in a very intense phase here, and the objective remains the same as before to leave the Russian market. In the meantime, from a volume perspective, the business is actually shrinking because of the market conditions. But because of currencies and price increases, you can see from a sales point of view, this number that you mentioned. So that intention is clear and that process is ongoing. When it comes to the market structure, we believe that there is a clear difference between the branded market where we are clearly the #1, the partnerships we have with some retailers since decades and the pure private label business, and we see this also to some extent in other categories. And with those clear differences, we are partly working in different segments. So I don't see in the short to medium term, a risk here, which I guess you're kind of maybe alluding to of kind of creating a competitor. So that's our view. And of course, we believe that those consumers who prefer the premium innovative branded products will continue to do so also going forward.
Next up, we have Karri Rinta from SHB.
Yes. Karri, Handelsbanken. Very quickly on the consumer goods and more specifically, this continued difference in pricing for consumer tissue private label versus branded consumer tissue. So is that a reflection of different contract structures, i.e., that the private label is more -- it goes quicker to adjust prices for private label and branded should follow or what's explaining this? And can you remind us of your contract structures for branded tissue and private label tissue?
I'm not sure...
Maybe we can give a general answer, Karri. So thanks for the question. I think we never comment on contract structures. Typically, we've said before that we have yearly contracts, but it varies. So there are differences here. But one of the reasons why the Consumer Tissue private label division has actually achieved somewhat higher prices than the rest is simply also because the raw material content is significantly higher for that business. So if you imagine a branded business, you have more cost for innovation or for marketing or for A&P as an example. And so -- and the typical average selling price is also higher. So if you take the raw material content, as percentage of the sales price, it's obviously higher for private label. So the need for price increases in that part of the business is obviously higher, and this is part of the explanation.
And thanks, Fredrik. Sorry, Karri, I didn't completely get the question, but a good answer. Thanks.
[Operator Instructions] We will now take the follow-up question from Karri Rinta from SHB.
Yes. To Fredrik's comment about the annual prices. So I guess, question is that have you gone back to having annual contracts? Because the -- I guess the message last year was that you're shortening the duration of your tissue contracts.
I guess that -- I mean we are -- what happened during the last 2 years is that we were kind of continuously negotiations because we were always behind the cost curve. And now we feel that we're in a quite stable situation for the time being and that without getting into any specific details because it varies so much between markets, between brands, between geographies we are very focused now on kind of managing, again, the price cost gap and the overall margin development. And we see good opportunity to do that because our brands are strong, but also actually recently, and I think I mentioned this before that we have quite good service levels compared to many competitors. And we are perceived as a dependable supplier that can deliver when there has been some hiccups over the last couple of years. So we are managing that price cost gap from a good position, I believe.
Next up, we have Niklas Ekman from Carnegie.
Yes. First, a question on volume. I believe after Q4, you said you still expected to deliver volume growth in 2023. I'm curious if that's still the view given that you have now seen volumes continuing lower in Q1? And do you expect volumes to reverse already from Q2?
We stick to the fact that we hope to have positive volume development for the full year. How this will vary now over the quarters is very, very difficult to say because, of course, there are quite some fluctuation normally and also seasonality. So I think that's very difficult to talk about individual quarters. But in the longer term and also for the year, we would like to see growing volumes. And that's because we always try to manage, of course, volumes, market shares, pricing and to find that balance. And when it comes to underlying volumes since we are providing essentials and necessities, as you know, we expect there to be an underlying stable or growing volume in many of our categories.
And just a second question also, you mentioned here in the presentation, you talked about Professional Hygiene and the Cure or Kill initiative indicating that you're looking at closing or divesting business. Is that a sizable business? And can you give any more details about what kind of business we're talking about?
Yes. As I said, Niklas, I did actually comment on it. I said it will have -- from a volume perspective, low single-digit impact on volumes for Professional Hygiene during this year, so the rest of 2023 and also at the beginning of 2024. So yes, it's -- from that perspective, we'll have a bit of volume impact and sales impact.
Maybe you could mention the restructuring charges?
Yes, I can repeat that if -- I'm not sure if you were on the call, Niklas, before but I talked about the restructuring cost that we will take. And the total cost is roughly about SEK 410 million and out of that, we will take SEK 340 million as items affect comparability during Q2. So that's the cost for it. And it's relating to not actually divestments, but rather closing of some, mainly converting equipment, you can say. And just to remind you one thing, this is what we are planning. We have not yet decided this, but this is what we are planning, so we'll come back more.
We will take our follow-up question from Karri Rinta from SHB.
Going back to return on capital employed, the unit that has the lowest return on capital employed right now is Health & Medical. And of course, we know that you still need to raise prices, and we should see higher margins in the future, and that will to some extent or that will help return on capital and employed as well, but you're still probably going to be quite a ways below the 70% target that you have for the group. So how do you plan to get to 17% in Health & Medical specifically?
We have very specific breakdowns of the overall target, but we're not providing that externally. So there are different return on capital employed targets for the different business areas and also different parts within the business areas. But that's kind of part of our internal work and it depends very much on different plans, but also on the market conditions. And of course, in the short to medium term, the next number of quarters, it's important to continue to work with the price increases, specifically in Health & Medical, where we still see a quite significant headwind from costs. So I think that's the information we can provide right now.
And maybe could add one thing, which is just reminding of one pretty obvious thing here that the reason why you would see this very low in comparison or not very low, but low in comparison return on capital employed for Health & Medical is that we have a very considerable intangible asset there as we purchased DSM. So if you would look at the return, operating return on capital, excluding intangibles, actually Health & Medical is clearly very high or highest in the group. So from a return perspective, it's actually doing really well, but we have the intangible assets, but just as a kind of a background to what you said, Magnus.
Of course.
We have a follow-up question from Victoria Nice from SG.
Just wondered if you could go into a bit more detail on other costs and any other elements that we need to bear in mind in Q2 and through the rest of the year because presumably, we'll have the fallout of energy subsidies paid to suppliers last year from Q2, will this still fall in the other line?
Yes. And I did comment on it earlier that when you look at -- and I presume you're asking about other COGS there because if you look at our report, we split out kind of what is SG&A, et cetera, in A&P. And I've already commented on that. We will see there sequentially an increase. When it comes to other COGS and including the issues that you were you were mentioning there, we expect more stable environment as we go forward. So no real change sequentially Q2 versus Q1. So overall, a slightly higher cost because of the SG&A but in total, it should be relatively flat. So of course, time will tell, but this is approximately the outlook.
[Operator Instructions] It appears that there are no further questions at this time. I would like to turn the conference back to our speaker for any additional or closing remarks.
So as a closing remark, we have a very strong start to 2023, very strong top line improvement, strong margin improvement. We're seeing a kind of more helpful market outlook for the coming quarters and rest of the year. And we are starting now a strategic review of our tissue -- Consumer Tissue assets, Vinda and the Private Label division in Europe, and we will come back with more information over time. Thank you very much for listening.